Coca-Cola remains resilient amid GLP-1 health trends and geopolitical risks, with proactive innovation and a diversified ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners.

Newly public Omada Health says it won't turn patient care over to AI as the tech consumes investor interest.

Younger generations, including my own, shouldn’t gloat, though: Cuts to Social Security and a halt to medical research could ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

TheStreet. Even the Hamburglar didn’t see this one coming. Excessive weight has been a persistent problem in America, where ...

Medtronic plc a global leader in medical technology, announced its intent to spin off its Diabetes business into a entity ...

Patent and trademark enforcement has become an important economic tool for entrepreneurs.

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.